← Back

Jiangsu GDK Biotechnology Co Ltd

Jiangsu GDK Biotechnology Co., Ltd. researches, develops, produces, and sells human vaccines. Its offerings include quadrivalent influenza virus split vaccines. The company's human vaccine products are used to prevent various infectious diseases, including influenza, rabies, chickenpox, shingles, and pneumonia. Founded in 2008, it is based in Taizhou, China.

Price · split & dividend adjusted
News & notes moving 688670.CG
688670.CG▼

Jindike's 2026 interim report shows net loss of 51.07 million yuan, widening year-on-year

Jindike released its 2026 interim report, with net profit attributable to the parent company at negative 51.07 million yuan, a loss expansion of 11.42 million yuan compared with the same period last year. The company's total operating revenue was 910,900 yuan, down 74.15 percent year-on-year. Net cash flow from operating activities was negative 35.31 million yuan, an increase of 50.18 million yuan over the same period last year, achieving two consecutive years of growth. The company's latest asset-liability ratio was 20.66 percent, gross margin was negative 279.01 percent, ROE was negative 4.87 percent, and diluted earnings per share was negative 0.41 yuan.
688670.CG ▼
Jiemian·28dRead more →
688670.CG▼

Jindike reports first-half net loss attributable to shareholders of about 51.07 million yuan

Jindike released its 2026 semi-annual report, showing a net loss attributable to shareholders of about 51.07 million yuan in the first half, compared with a loss of about 39.65 million yuan in the same period last year. The company achieved operating revenue of about 910,900 yuan in the first half, down 74.15 percent year on year. Jindike focuses on the research, development, production and sales of human vaccines, with main products including 10 human vaccine products targeting five infectious diseases: influenza, rabies, chickenpox, shingles and pneumonia. The company said the decline in operating revenue was mainly due to lower sales volume during the reporting period.
688670.CG ▼
北京商报·29dRead more →
688670.CG▲

Multiple regions release 2026 flu vaccine procurement intentions with budget price around 9 yuan per dose

Multiple regions have released procurement intentions for the 2026 to 2027 flu season, with the budget unit price for trivalent influenza split-virus vaccine at approximately 9 yuan per dose. According to an incomplete tally by Red Star Capital Bureau, as of press time no fewer than 10 provinces have issued relevant procurement intentions, mainly targeting key groups such as rural residents aged 65 and above and primary and secondary school students in compulsory education. The main vaccine type procured is the 0.5 milliliter trivalent influenza split-virus vaccine for adults and children aged three and above. Among them, Hunan Province plans to procure 3.7611 million doses with a budget of 33.84 million yuan; Hubei Province plans to procure 2.8135 million doses with a budget of 25.32 million yuan; Heilongjiang Province plans to procure 1.0264 million doses with a budget of 9.2374 million yuan. Although Anhui, Hainan, Shaanxi and other regions have not disclosed specific dose numbers, they have listed budgets of 30.42 million yuan, 4.77 million yuan and 18.3425 million yuan respectively. This budget price has stabilized from last year's low of 5.5 yuan per dose, while the price of quadrivalent flu vaccines in the self-pay market remains relatively stable, with adult pre-filled syringes priced between 85 and 88 yuan per dose.
301207.CS ▲688670.CG ▲
红星资本局·54dRead more →
© 2026 MarketDXAsset